Biontech announces third quarter 2023 financial results and corporate update

Positive clinical data updates across multiple drug classes including antibody-drug conjugate (adc) candidates bnt323/db-1303, bnt325/db-1305, car-t candidate bnt211, t cell therapy candidate bnt221 and mrna cancer vaccine candidate bnt116 progress across the oncology pipeline with multiple late-stage trials initiated since third quarter start new and expanded strategic collaborations reflect biontech's commitment to delivering transformational therapies for oncology and infectious diseases successful launches of omicron xbb.1.5-adapted monovalent covid-19 vaccine in markets worldwide updated 2023 covid-19 vaccine revenue guidance of around €4 billion guidance reduction of planned 2023 r&d expenses to €1.8-2.0 billion and sg&a expenses to €600-650 million first nine months of 20231 revenues of €2.3 billion2, net profit of €472 million and diluted earnings per share of €1.94 ($2.113) conference call and webcast scheduled for november 6, 2023, at 8:00 am et (2:00 pm cet) mainz, germany, november 6, 2023 (globe newswire) --  biontech se (nasdaq: bntx, “biontech” or “the company”) today reported financial results for the three and nine months ended september 30, 2023, and provided an update on its corporate progress. “over the last quarter, we complemented our investigational pipeline with adc candidates, initiated later-stage clinical trials and presented significant data across modalities including cancer vaccines, cell therapies, adcs and immune checkpoint modulators.
BNTX Ratings Summary
BNTX Quant Ranking